Compare Fulford India with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA STRIDES PHARMA SCIENCE FULFORD INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 398.8 44.5 896.7% View Chart
P/BV x 6.2 2.1 299.4% View Chart
Dividend Yield % 0.1 0.2 36.2%  

Financials

 FULFORD INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
STRIDES PHARMA SCIENCE
Mar-18
FULFORD INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs9421,147 82.1%   
Low Rs450642 70.1%   
Sales per share (Unadj.) Rs691.4317.2 217.9%  
Earnings per share (Unadj.) Rs11.57.8 146.1%  
Cash flow per share (Unadj.) Rs15.425.1 61.3%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.2 128.5%  
Book value per share (Unadj.) Rs380.0274.3 138.6%  
Shares outstanding (eoy) m3.9089.50 4.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.02.8 35.7%   
Avg P/E ratio x60.7114.0 53.3%  
P/CF ratio (eoy) x45.335.7 126.9%  
Price / Book Value ratio x1.83.3 56.2%  
Dividend payout %17.425.5 68.4%   
Avg Mkt Cap Rs m2,71480,058 3.4%   
No. of employees `0000.42.5 17.7%   
Total wages/salary Rs m5054,341 11.6%   
Avg. sales/employee Rs Th6,073.011,325.8 53.6%   
Avg. wages/employee Rs Th1,137.41,731.4 65.7%   
Avg. net profit/employee Rs Th100.7280.1 35.9%   
INCOME DATA
Net Sales Rs m2,69628,394 9.5%  
Other income Rs m125941 13.3%   
Total revenues Rs m2,82229,334 9.6%   
Gross profit Rs m-463,965 -1.2%  
Depreciation Rs m151,540 1.0%   
Interest Rs m101,962 0.5%   
Profit before tax Rs m541,403 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1097 9.9%   
Profit after tax Rs m45702 6.4%  
Gross profit margin %-1.714.0 -12.3%  
Effective tax rate %17.76.9 255.0%   
Net profit margin %1.72.5 67.0%  
BALANCE SHEET DATA
Current assets Rs m1,73824,836 7.0%   
Current liabilities Rs m54518,993 2.9%   
Net working cap to sales %44.320.6 215.1%  
Current ratio x3.21.3 244.1%  
Inventory Days Days4871 68.3%  
Debtors Days Days4113 3.8%  
Net fixed assets Rs m1234,289 0.0%   
Share capital Rs m39895 4.4%   
"Free" reserves Rs m1,44323,651 6.1%   
Net worth Rs m1,48224,546 6.0%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m2,07765,437 3.2%  
Interest coverage x6.71.7 391.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.4 299.2%   
Return on assets %2.64.1 64.1%  
Return on equity %3.02.9 105.4%  
Return on capital %4.36.9 62.4%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1715,697 0.1%   
Fx outflow Rs m673735 91.5%   
Net fx Rs m-65614,962 -4.4%   
CASH FLOW
From Operations Rs m901,871 4.8%  
From Investments Rs m1055,826 1.8%  
From Financial Activity Rs m-14-10,157 0.1%  
Net Cashflow Rs m181-2,615 -6.9%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 37.8 10.1%  
FIIs % 0.1 8.6 1.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 25.9 81.9%  
Shareholders   4,783 56,241 8.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS